Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Adicet Bio Inc. (NASDAQ:ACET) shares fell Tuesday after the biotechnology company priced an $80 million direct offering, even as early safety and efficacy data from its Phase 1 trial of ADI-001 in autoimmune diseases showed encouraging signs.

The company priced a registered direct offering of 70 million shares and pre-funded warrants to purchase 10 million shares at $1.00 per share and $0.9999 per warrant, respectively, for expected gross proceeds of approximately $80 million.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.